Page 155 - CW E-Magazine (12-11-2024)

Pharmaceuticals

GROWTH STRATEGY
Piramal Pharma plans $85-mn capex in current fi nancial year

Piramal Pharma is utilising a capex “We expect the capex this year to Piramal Pharma Solutions (PPS)
of about $85-mn for various initiatives, be at a similar level as last year, which has already announced an investment
including capacity expansion, mainte- is about $85 million,” Ms. Piramal told of $80-mn in expanding its sterile
nance and de-bottlenecking of CDMO news agency, PTI. injectables facility in Lexington,
sites, in the current fi scal, according to Kentucky (US). “It will be completed
its Chairperson, Ms. Nandini Piramal. A part of the capex is planned for the in FY27,” Ms. Piramal said.
domestic market while some of it would
Piramal Pharma includes Piramal also go into the US business, she added. Aiming high
Pharma Solutions (PPS), an integrated “Some part of it, around $30-mn, is Piramal Pharma is aiming to be
contract development and manufacturing maintenance capex, and the rest would an over $2-bn global pharma, health
organisation (CDMO); Piramal Critical go into capacity expansion in Telangana and wellness fi rm by FY30. In the next
Care (PCC), a complex hospital generics and Dahej (Gujarat) plants and also to- fi ve years, the company is targeting its
business; and the India Consumer Health- wards de-bottlenecking of some of the CDMO vertical to become a $1.2-bn
care business selling over-the-counter CDMO sites,” Ms. Piramal noted. The entity. Besides, the company expects its
products. company recently reported over four- critical care vertical to touch $600-mn
fold increase in consolidated net profi t by FY30 and the consumer healthcare
The Mumbai-based fi rm, which aims at Rs. 23-crore for the second quarter vertical to become a $200-mn entity.
to cross $2-bn in revenue by FY30, has ended September. It reported revenue of
already invested around $30-mn in the Rs. 2,242-crore for the second quarter, Ms. Piramal stated that the company
fi rst half of the ongoing fi scal on the compared to Rs. 1,911-crore in the same also continues to look at inorganic growth
initiatives. year-ago period. to achieve its stated targets.
Mankind Pharma closes acquisition of Bharat Serums and Vaccines

Mankind Pharma said it has com- Mankind Pharma’s Vice-Chairman and ensure wider access of our specialised
pleted the transaction to acquire Bharat Managing Director, Mr. Rajeev Juneja, and indigenously developed complex
Serums and Vaccines Ltd. (BSV), for stated. treatments to millions of patients in India
Rs. 13,768-crore. The deal positions the and across the globe,” added Mr. Sanjiv
company as a market leader in the Indian “Together, we will now be able to Navangul, MD & CEO, BSV.
women’s health and fertility drug market
besides providing access to other high Alembic Pharma gets USFDA nod for generic
entry barrier products in critical care
segment with established complex R&D hypertension treatment capsules
tech platforms, the company informed in
a statement. Alembic Pharmaceuticals said it (RLD), ‘Dilacor XR Extended-Release’
has received fi nal approval from the US capsules, 120-mg, 180-mg, and 240-mg
The deal to acquire 100% stake in BSV health regulator for its generic version of Allergan Sales LLC, it added.
was announced by Mankind in July this of Diltiazem Hydrochloride extended-
year. BSV has developed recombinant and release capsules used to treat hyperten- Diltiazem Hydrochloride extended-
niche biologic products in-house, demon- sion. The approval by the USFDA is release capsules are indicated for treat-
strating its strong R&D capabilities and for the abbreviated new drug applica- ment of hypertension. The drug may be
boasts of a robust branded product port- tion (ANDA) Diltiazem Hydrochloride used alone or in combination with other
folio across women’s health, fertility, extended-release capsules of strengths antihypertensive medications, such as
critical care and immunoglobulins. “We 120-mg, 180-mg, and 240-mg, the diuretics. It is also indicated for the man-
warmly welcome BSV’s 2,500-plus company said. agement of chronic stable angina. Citing
members to Mankind family adding a IQVIA data, Alembic Pharma said the
new chapter to our exciting journey and These are therapeutically equiva- capsules have an estimated market size of
setting the stage for accelerated growth,” lent to the reference listed drug product $28.2-mn for 12 months ended June 2024.

Chemical Weekly November 5, 2024 155

Contents Index to Advertisers Index to Products Advertised